Redcare Pharmacy N.V. has increased its full-year 2026 revenue guidance for the second time this year, citing continued strength in prescription (Rx) revenue in Germany. The upgrade reflects preliminary figures showing Rx revenue in Germany grew 51% year-on-year in September and 56% in the third quarter. The company now expects Rx revenue in Germany to reach EUR 730 to 760 million for the full year, up from the previous range of EUR 680 to 720 million. This represents growth of 45% to 51%, compared to the earlier guidance of 35% to 43%.
The revised outlook underscores the accelerating adoption of digital prescription services, with the electronic prescription (eRx) net promoter score (NPS) rising 6 points year-on-year to 80 in August. According to CEO Olaf Heinrich, “Our growth is backed by strong customer satisfaction: eRx NPS continues to rise.” The strong Rx performance came despite a high comparison base from the prior year, when the current Rx bonus was introduced, highlighting the durability of this momentum. Non-Rx revenue in Germany also rebounded in August and September after a softer July, though its growth guidance remains unchanged at 10% to 12%.
The overall revenue growth guidance for 2026 was lifted to 16% to 18%, from 15% to 17% previously. Adjusted EBITDA margin guidance remains unchanged at 2.5% to 3.0%, with the company noting that the margin benefited from continued operating leverage and remained flat quarter-on-quarter. The guidance raise is significant because it demonstrates Redcare’s ability to capitalize on the structural shift toward online pharmacy services in Europe’s largest healthcare market. Germany is a key battleground for digital health, and Redcare’s strong Rx performance suggests it is gaining share and building customer loyalty through reliable e-prescription handling. The company will publish its full third-quarter 2026 interim statement and host a conference call on October 29, 2026, providing further details on its financial and operational progress.
Investors and industry observers will be watching closely, as the revised guidance may signal broader trends in online pharmacy adoption and the growing role of digital prescriptions. Redcare Pharmacy, which generated EUR 2.9 billion in revenues in 2025 and serves over 14 million active customers across seven European countries, continues to position itself as a leader in the digital pharmacy space. The company’s focus on pharmaceutical safety and comprehensive services has helped it expand its prescription drug offerings in Germany, Switzerland, and the Netherlands. The second guidance raise this year highlights management’s confidence in sustained growth, even as it balances investment in customer experience with margin discipline.
The original release can be viewed on www.newmediawire.com, and further updates are expected at the upcoming quarterly call. As the online pharmacy market evolves, Redcare’s performance could set the tone for competitors and influence investor sentiment toward digital health stocks in Europe.
